FORA Capital LLC Invests $54,000 in Revance Therapeutics, Inc. (NASDAQ:RVNC)

FORA Capital LLC acquired a new stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,367 shares of the biopharmaceutical company’s stock, valued at approximately $54,000.

Other large investors have also recently added to or reduced their stakes in the company. LMR Partners LLP purchased a new position in shares of Revance Therapeutics in the 3rd quarter valued at about $11,648,000. Integral Health Asset Management LLC acquired a new stake in Revance Therapeutics in the second quarter valued at approximately $1,285,000. Vanguard Group Inc. lifted its stake in Revance Therapeutics by 6.5% in the first quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock worth $26,560,000 after acquiring an additional 328,781 shares during the last quarter. Alpine Associates Management Inc. acquired a new position in Revance Therapeutics during the 3rd quarter worth approximately $21,605,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Revance Therapeutics by 28.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 69,361 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 15,496 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Stock Down 4.5 %

RVNC opened at $3.61 on Friday. The firm has a market cap of $378.70 million, a price-to-earnings ratio of -1.87 and a beta of 0.95. Revance Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $9.74. The business’s 50 day moving average is $4.92 and its two-hundred day moving average is $4.44.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. Equities analysts expect that Revance Therapeutics, Inc. will post -1.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus decreased their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Piper Sandler downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Finally, Guggenheim reissued a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.66.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.